Creative Medical Technology Holdings, Inc. (CELZ) Bundle
A Brief History of Creative Medical Technology Holdings, Inc.
Creative Medical Technology Holdings, Inc. (the "Company") has a history rooted in innovation within the biotechnology sector. Incorporated on December 3, 1998, as Jolley Marketing, Inc., the Company underwent a significant transformation on May 18, 2016, through a reverse merger with Creative Medical Technologies, Inc. This merger led to a rebranding to reflect its focus on advancing biological therapeutics, particularly in immunotherapy and endocrinology.
Recent Developments (2024)
In 2024, the Company achieved notable milestones in its clinical trials and product development:
- In March 2024, the Company received FDA authorization for an expanded access therapy using CELZ-201, aimed at managing abnormal glucose tolerance and preventing Type I Diabetes in high-risk individuals.
- In June 2024, the Company successfully generated human induced pluripotent stem cells (iPSC)-derived Islet Cells, which produce human insulin.
- In July 2024, a program was initiated to diagnose and treat patients exposed to biological and chemical weapons, leveraging AI and proprietary iPSC technology.
Financial Performance
As of September 30, 2024, the Company's financial performance reflects ongoing investment in research and development, alongside operational losses:
| Financial Metric | September 30, 2024 | September 30, 2023 |
|---|---|---|
| Net Revenue | $8,000 | $6,000 |
| Cost of Goods Sold | $3,200 | $2,400 |
| Gross Profit | $4,800 | $3,600 |
| Operating Loss | $3,858,127 | $3,848,293 |
| Net Loss | $3,639,407 | $3,608,000 |
| Cash Balance | $6,260,438 | $4,507,108 |
Stockholder Equity
As of September 30, 2024, the Company's stockholder equity is summarized as follows:
| Equity Component | Amount |
|---|---|
| Common Stock | $1,431 |
| Additional Paid-In Capital | $69,739,235 |
| Accumulated Deficit | ($62,737,839) |
| Treasury Stock | ($445,916) |
| Total Stockholder Equity | $6,557,011 |
Share Repurchase Program
In 2024, the Company initiated a share repurchase program, purchasing a total of 101,250 shares at an average price of $4.40 per share. The following table outlines the monthly share repurchases:
| Period | Total Shares Purchased | Average Price Paid per Share |
|---|---|---|
| July 2024 | 500 | $2.83 |
| August 2024 | 5,250 | $3.16 |
| September 2024 | 2,500 | $2.83 |
| 2024 YTD Total | 43,750 | $4.00 |
The Company's commitment to advancing its therapeutic offerings while managing financial performance highlights its strategic direction as of 2024.
A Who Owns Creative Medical Technology Holdings, Inc. (CELZ)
Ownership Structure
As of 2024, Creative Medical Technology Holdings, Inc. (CELZ) has a relatively simple ownership structure. The company has issued 1,431,126 shares of common stock and one share of Series B preferred stock. The Series B preferred stock was purchased by Timothy Warbington, the CEO and Chairman, for $100. This share grants him special voting rights concerning proposals to increase the authorized shares of common stock.
| Type of Stock | Shares Issued | Shareholder | Voting Rights | Purchase Price |
|---|---|---|---|---|
| Common Stock | 1,431,126 | Public Investors | Standard | N/A |
| Series B Preferred Stock | 1 | Timothy Warbington | 100,000,000 votes on Share Increase Proposal | $100 |
Financial Overview
As of September 30, 2024, Creative Medical Technology Holdings reported total assets of $6,887,919, with total liabilities amounting to $330,908. The company has accumulated a deficit of $62,737,839, which reflects its ongoing operational losses. The total stockholders' equity is recorded at $6,557,011.
| Financial Metric | Amount (as of September 30, 2024) |
|---|---|
| Total Assets | $6,887,919 |
| Total Liabilities | $330,908 |
| Accumulated Deficit | $(62,737,839) |
| Total Stockholders' Equity | $6,557,011 |
Recent Performance
For the nine months ended September 30, 2024, the company generated revenues of $8,000, an increase from $6,000 in the prior year. However, the operating loss for the same period was $3,858,127, compared to $3,848,293 for the previous year, indicating a slight increase in operational losses despite the revenue growth.
| Performance Metric | Amount (Nine Months Ended September 30, 2024) | Amount (Nine Months Ended September 30, 2023) |
|---|---|---|
| Revenue | $8,000 | $6,000 |
| Operating Loss | $(3,858,127) | $(3,848,293) |
Share Repurchase Program
In 2023, the company authorized a share repurchase program for up to $2 million of its common stock. By September 30, 2024, the company had repurchased a total of 101,250 shares under this program, at an average price of approximately $4.40 per share.
| Repurchase Program Summary | Details |
|---|---|
| Shares Repurchased | 101,250 |
| Average Price Paid per Share | $4.40 |
| Maximum Dollar Value Remaining | $1,554,084 |
Conclusion on Ownership
Creative Medical Technology Holdings, Inc. is primarily owned by public investors through its common stock, while key management, particularly Timothy Warbington, holds a significant position through the Series B preferred stock. The company continues to focus on its clinical and operational objectives despite ongoing financial challenges.
Creative Medical Technology Holdings, Inc. (CELZ) Mission Statement
Company Overview
Creative Medical Technology Holdings, Inc. (CELZ) is a biotechnology company focused on developing innovative therapies utilizing stem cells and regenerative medicine. The company aims to advance the treatment of various conditions, including erectile dysfunction, chronic back pain, Type 1 diabetes, and other disorders through its patented technologies.
Mission Statement
As of 2024, Creative Medical Technology Holdings, Inc. is committed to improving patient outcomes through the development of novel biological therapeutics. The mission emphasizes the use of cutting-edge research to harness the power of stem cells and immune cells, translating scientific advancements into effective clinical applications.
Financial Performance Overview
For the nine-month period ended September 30, 2024, CELZ reported the following financial data:
| Financial Metric | Q3 2024 | Q3 2023 |
|---|---|---|
| Gross Revenue | $8,000 | $6,000 |
| Cost of Goods Sold | $3,200 | $2,400 |
| Gross Profit | $4,800 | $3,600 |
| Selling, General, and Administrative Expenses | $1,846,177 | $2,161,599 |
| Research and Development Expenses | $1,928,937 | $1,621,231 |
| Operating Loss | ($3,858,127) | ($3,848,293) |
| Net Loss | ($3,639,407) | ($3,608,000) |
Operational Highlights
Creative Medical Technology Holdings is advancing multiple clinical trials and has made significant progress in its research initiatives. Notable developments include:
- FDA clearance for the CELZ-201 ADAPT trial targeting chronic lower back pain.
- Positive one-year follow-up data for the CELZ-001 trial in Type 2 diabetes, showing a 93% efficacy rate in reducing insulin requirements.
- Receipt of Orphan Drug Designation from the FDA for the treatment of Brittle Type 1 Diabetes.
Stockholder Information
As of September 30, 2024, the company’s stockholder equity and capitalization structure is as follows:
| Equity Metric | Amount |
|---|---|
| Common Stock Issued | 1,431,126 shares |
| Series B Preferred Stock Issued | 1 share |
| Additional Paid-in Capital | $69,739,235 |
| Accumulated Deficit | ($62,737,839) |
| Treasury Stock | ($445,916) |
| Total Stockholders' Equity | $6,557,011 |
Future Directions
Looking forward, Creative Medical Technology Holdings, Inc. plans to continue its dedication to research and clinical development, focusing on expanding its portfolio of regenerative therapies and enhancing patient care through innovative treatments. The company remains committed to leveraging its proprietary technologies to address unmet medical needs across various therapeutic areas.
How Creative Medical Technology Holdings, Inc. (CELZ) Works
Company Overview
Creative Medical Technology Holdings, Inc. (CELZ) is a biotechnology company focused on developing novel therapies utilizing stem cells and other regenerative medicine techniques. The company primarily operates through its subsidiary, Creative Medical Technologies, Inc. (CMT), which markets and sells medical kits for treating erectile dysfunction and female sexual dysfunction.
Financial Performance
As of September 30, 2024, the financial performance of CELZ is summarized in the following table:
| Financial Metric | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Gross Revenue | $0 | $6,000 | $8,000 | $6,000 |
| Cost of Goods Sold | $0 | $2,400 | $3,200 | $2,400 |
| Gross Profit | $0 | $3,600 | $4,800 | $3,600 |
| Research and Development Expenses | $581,796 | $992,272 | $1,928,937 | $1,621,231 |
| Selling, General and Administrative Expenses | $498,607 | $531,042 | $1,846,177 | $2,161,599 |
| Operating Loss | $(1,109,674) | $(1,546,785) | $(3,858,127) | $(3,848,293) |
| Net Loss | $(1,040,135) | $(1,453,952) | $(3,639,407) | $(3,608,000) |
Cash Flow Analysis
For the nine months ended September 30, 2024, CELZ reported the following cash flow metrics:
| Cash Flow Metric | 9M 2024 | 9M 2023 |
|---|---|---|
| Net Cash Used in Operating Activities | $(3,351,756) | $(6,132,902) |
| Net Cash Received from Investing Activities | $6,320,191 | $2,511,271 |
| Net Cash Used in Financing Activities | $(174,864) | $(191,780) | Ending Cash Balance | $6,260,438 | $4,507,108 |
Research and Development Initiatives
CELZ is engaged in several clinical trials and research initiatives, particularly focusing on stem cell therapies. Notable developments include:
- FDA authorization for expanded access therapy using CELZ-201 for Type I Diabetes prevention.
- Initiation of a Phase I/II clinical trial for AlloStemSpine™ Chronic Lower Back Pain (CELZ-201 ADAPT).
- Development of human induced pluripotent stem cells (iPSC)-derived Islet Cells for insulin production.
Stockholder Equity and Capital Structure
As of September 30, 2024, CELZ's stockholder equity is detailed below:
| Equity Metric | Amount |
|---|---|
| Common Stock | $1,431 |
| Series B Preferred Stock | $100 |
| Additional Paid-in Capital | $69,739,235 |
| Accumulated Deficit | $(62,737,839) |
| Treasury Stock | $(445,916) |
| Total Stockholders' Equity | $6,557,011 |
Market Performance
As of September 30, 2024, CELZ's stock performance has been impacted by various factors including clinical trial outcomes and financial results. The company has a total of 2,284,932 outstanding warrants with a weighted average exercise price of $26.59 and a remaining life of approximately 2.47 years.
How Creative Medical Technology Holdings, Inc. (CELZ) Makes Money
Revenue Generation
Creative Medical Technology Holdings, Inc. primarily generates revenue through the sale of its disposable stem cell concentration kits, specifically the CaverStem® and FemCelz® kits, which are utilized by physicians for autologous procedures treating erectile dysfunction and female sexual dysfunction, respectively. As of September 30, 2024, the company reported a total revenue of $8,000 for the nine-month period ending on that date, compared to $6,000 in the same period the previous year.
| Period | Revenue | Cost of Goods Sold | Gross Profit |
|---|---|---|---|
| Three months ended September 30, 2024 | $0 | $0 | $0 |
| Three months ended September 30, 2023 | $6,000 | $2,400 | $3,600 |
| Nine months ended September 30, 2024 | $8,000 | $3,200 | $4,800 |
| Nine months ended September 30, 2023 | $6,000 | $2,400 | $3,600 |
Research and Development Activities
The company is heavily invested in research and development (R&D) to advance its therapeutic technologies. For the three months ending September 30, 2024, R&D expenses totaled $581,796, compared to $992,722 in the same period in 2023. For the nine months ending September 30, 2024, R&D expenses were $1,928,937, up from $1,621,231 in 2023.
Operating Expenses
Creative Medical Technology Holdings, Inc. incurs significant operating expenses that impact its profitability. For the three months ended September 30, 2024, total operating expenses were $1,109,674, compared to $1,546,785 for the same period in 2023. The decrease is attributed to lower general and administrative expenses, which amounted to $498,607 in 2024 versus $531,042 in 2023.
| Expense Category | Three Months Ended September 30, 2024 | Three Months Ended September 30, 2023 | Nine Months Ended September 30, 2024 | Nine Months Ended September 30, 2023 |
|---|---|---|---|---|
| Research and Development | $581,796 | $992,722 | $1,928,937 | $1,621,231 |
| Selling, General and Administrative | $498,607 | $531,042 | $1,846,177 | $2,161,599 |
| Amortization of Patent Costs | $29,271 | $23,021 | $87,813 | $69,063 |
| Total Operating Expenses | $1,109,674 | $1,546,785 | $3,862,927 | $3,851,893 |
Net Loss
The company reported a net loss of $1,040,135 for the three months ended September 30, 2024, compared to a net loss of $1,453,952 for the same period in 2023. For the nine months ended September 30, 2024, the net loss was $3,639,407, slightly higher than the $3,608,000 loss reported in the prior year.
Investment and Funding
As of September 30, 2024, the company's cash balance stood at $6,260,438, down from $9,987,058 at the end of 2023. The company has utilized its cash for operating activities, including significant payments related to R&D and patent obligations.
| Financial Metric | September 30, 2024 | December 31, 2023 |
|---|---|---|
| Cash | $6,260,438 | $9,987,058 |
| Net Loss (Nine Months) | $3,639,407 | $3,608,000 |
| Current Liabilities | $330,908 | $371,394 |
| Total Assets | $6,887,919 | $10,715,190 |
Future Developments
The company is pursuing several clinical trials and has received FDA authorizations for therapies aimed at treating Type I Diabetes and chronic lower back pain. These developments are crucial for potential future revenue streams as the company aims to commercialize its innovative therapies.
Creative Medical Technology Holdings, Inc. (CELZ) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Creative Medical Technology Holdings, Inc. (CELZ) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Creative Medical Technology Holdings, Inc. (CELZ)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Creative Medical Technology Holdings, Inc. (CELZ)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.